{"id":"ocrevus-eu","safety":{"commonSideEffects":[{"rate":"approximately 35-40%","effect":"Infusion reactions"},{"rate":"approximately 25-30%","effect":"Upper respiratory tract infections"},{"rate":"approximately 10-15%","effect":"Lower respiratory tract infections"},{"rate":"approximately 10-15%","effect":"Headache"},{"rate":"approximately 10%","effect":"Fatigue"},{"rate":"approximately 2-3%","effect":"Herpes zoster"}]},"_chembl":{"chemblId":"CHEMBL5857501","moleculeType":null,"molecularWeight":"542.39"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ocrevus (ocrelizumab) targets CD20, a surface antigen on B cells, leading to their depletion through antibody-dependent cellular cytotoxicity and direct cell death. By reducing B cell populations, it decreases the production of autoantibodies and pro-inflammatory cytokines that drive multiple sclerosis pathology. This mechanism helps reduce relapse rates and slow disability progression in both relapsing and primary progressive MS.","oneSentence":"Ocrevus is a monoclonal antibody that depletes B cells by binding to CD20, reducing immune-mediated inflammation in multiple sclerosis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:23:52.718Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing-remitting multiple sclerosis (RRMS)"},{"name":"Primary progressive multiple sclerosis (PPMS)"}]},"trialDetails":[{"nctId":"NCT06700343","phase":"PHASE3","title":"Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)","status":"RECRUITING","sponsor":"Amgen","startDate":"2025-01-13","conditions":"Relapsing-remitting Multiple Sclerosis (RRMS)","enrollment":444},{"nctId":"NCT06847724","phase":"PHASE3","title":"Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis","status":"RECRUITING","sponsor":"Sandoz","startDate":"2025-06-10","conditions":"Relapsing Multiple Sclerosis","enrollment":175},{"nctId":"NCT05906992","phase":"PHASE3","title":"A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis","status":"RECRUITING","sponsor":"Celltrion","startDate":"2024-01-11","conditions":"Relapsing-remitting Multiple Sclerosis","enrollment":512}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ocrelizumab"],"phase":"phase_3","status":"active","brandName":"Ocrevus-EU","genericName":"Ocrevus-EU","companyName":"Sandoz","companyId":"sandoz","modality":"Biologic","firstApprovalDate":"","aiSummary":"Ocrevus is a monoclonal antibody that depletes B cells by binding to CD20, reducing immune-mediated inflammation in multiple sclerosis. Used for Relapsing-remitting multiple sclerosis (RRMS), Primary progressive multiple sclerosis (PPMS).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}